CD19 and non-Hodgkin lymphoma: Another trial treating intermediate or low-grade NHL, ALL, or CLL with anti-CD19 CAR T cells and the CTLA-4-directed antibody ipilimumab 2 weeks after T cell injection (NCT00586391) is still in progress.